Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 17/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388777 | 0.86 | AR (0.70) | ARPGR | |
| SCHEMBL2390678 | 0.86 | AR (0.47) | ARCHRM4PGRHTR2A | |
| SCHEMBL2392083 | 0.84 | AR (0.54) | AR | |
| SCHEMBL2391268 | 0.82 | AR (0.54) | ARCHRM4 | |
| SCHEMBL2390428 | 0.80 | AR (0.52) | ARCHRM4 | |
| SCHEMBL2388965 | 0.76 | AR (0.50) | ARPGR | |
| SCHEMBL2392410 | 0.76 | AR (0.50) | ARPGR | |
| SCHEMBL13651274 | 0.74 | AR (0.72) | AR | |
| SCHEMBL13651289 | 0.74 | AR (0.50) | ARCHRM4HTR2A | |
| SCHEMBL2392473 | 0.74 | AR (0.48) | ARCHRM4PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2098507-B1 | Cyclic amine compound as androgen receptor modulator | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-2098507-B1 | Cyclic amine compound as androgen receptor modulator | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-8013008-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8013008-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8013008-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-2098507-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | AR, FSHR, NR5A1 | AR 1/4885CHRM4 221/4885PGR 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.